Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NDL013
MIFTS: 47

Nodular Regenerative Hyperplasia

Categories: Liver diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nodular Regenerative Hyperplasia

About this section

MalaCards integrated aliases for Nodular Regenerative Hyperplasia:

Name: Nodular Regenerative Hyperplasia 52 71
Nodular Regenerative Hyperplasia of the Liver 52 58
Non-Cirrhotic Nodulation 52 58
Non-Cirrhotic Nodular Transformation 52
Miliary Hepatocellular Adenomatosis 52
Non-Cirrhotic Portal Hypertension 52
Nodular Hyperplasia 71

Characteristics:

Orphanet epidemiological data:

58
nodular regenerative hyperplasia of the liver
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare hepatic diseases


External Ids:

ICD10 via Orphanet 33 K76.8
Orphanet 58 ORPHA48372
SNOMED-CT via HPO 68 34742003
UMLS 71 C0020510 C4048264
Sources

Summaries for Nodular Regenerative Hyperplasia

About this section
NIH Rare Diseases : 52 Nodular regenerative hyperplasia (NRH) is a rare liver disease in which normal liver tissue transforms into multiple, small clusters (nodules) of replicating liver cells (regenerating hepatocytes). It can develop in people of all ages but is more common in older adults. NRH often does not cause signs or symptoms (so is likely underdiagnosed), but in some people, it leads to a type of portal hypertension called non-cirrhotic portal hypertension (NCPH). NCPH refers to abnormally high blood pressure in the portal vein (the vein that carries blood from the intestine to the liver) that is not caused by cirrhosis (scarring of liver tissue that impairs its function). NCPH typically is less severe than portal hypertension caused by cirrhosis. Symptoms of portal hypertension may include fatigue, edema , itching, jaundice , and abdominal discomfort or swelling due to fluid build-up (ascites ). Complications that may develop include bleeding esophageal varices and an enlarged and overactive spleen (hypersplenism ). Liver function in most people with NRH remains normal (even in those who develop NCPH), and liver failure in people with NRH and NCPH is rare. The cause of NRH is not well-understood. It is thought that the liver's blood vessels somehow become damaged or inflamed, impairing blood flow to parts of the liver. This in turn may cause cells in adjacent parts to "overcompensate" and replicate more than they should, leading to NRH. While some people with NRH have no known underlying health problems, NRH is often associated with rheumatic , autoimmune, hematologic (blood-related), and myeloproliferativ e disorders; chronic or recurrent infections; immune deficiency; or exposure to certain medications or toxins . NRH may be diagnosed based on signs and symptoms (when present), liver function tests (which usually are normal), medical history (including drug or toxin exposure), imaging studies, and liver biopsy (to rule out cirrhosis). Treatment for people with NCPH may involve starting medications to prevent or treat bleeding esophageal varices, stopping medications associated with NCPH, and treating underlying health conditions associated with NCPH. The long-term outlook for people with NRH depends on whether an underlying health problem is present and whether NCPH and its complications develop (which cannot be predicted). A small proportion of people eventually need a liver transplant .

MalaCards based summary : Nodular Regenerative Hyperplasia, also known as nodular regenerative hyperplasia of the liver, is related to hepatic veno-occlusive disease and budd-chiari syndrome. An important gene associated with Nodular Regenerative Hyperplasia is NOTCH1 (Notch Receptor 1), and among its related pathways/superpathways are Th17 cell differentiation and Notch Signaling Pathway (WikiPathways). The drugs Caffeine and Analgesics, Non-Narcotic have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and bone, and related phenotypes are portal hypertension and abnormality of the hepatic vasculature

Wikipedia : 74 Nodular regenerative hyperplasia is a form of liver hyperplasia associated with portal hypertension.... more...

Sources

Related Diseases for Nodular Regenerative Hyperplasia

About this section

Diseases related to Nodular Regenerative Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 hepatic veno-occlusive disease 30.1 TPMT F3
2 budd-chiari syndrome 30.0 GFER F3
3 adams-oliver syndrome 29.5 NOTCH2 NOTCH1 JAG1
4 alagille syndrome 1 29.4 NOTCH2 NOTCH1 JAG1
5 portal hypertension 11.1
6 varicose veins 10.7
7 splenomegaly 10.6
8 esophageal varix 10.6
9 liver cirrhosis 10.6
10 felty syndrome 10.6
11 autoimmune disease 10.6
12 inflammatory bowel disease 10.6
13 primary biliary cirrhosis 10.5
14 cholestasis 10.5
15 hepatoportal sclerosis 10.5
16 liver disease 10.5
17 immune deficiency disease 10.5
18 common variable immunodeficiency 10.4
19 systemic lupus erythematosus 10.4
20 pulmonary hypertension 10.4
21 vascular disease 10.4
22 hypersplenism 10.4
23 lupus erythematosus 10.4
24 encephalopathy 10.4
25 hepatic coma 10.4
26 hepatic encephalopathy 10.4
27 adenoma 10.4
28 peliosis hepatis 10.4
29 thrombophilia due to thrombin defect 10.3
30 hepatocellular carcinoma 10.3
31 celiac disease 1 10.3
32 crest syndrome 10.3
33 portal vein thrombosis 10.3
34 telangiectasis 10.3
35 thrombocytopenia 10.3
36 banti's syndrome 10.3
37 scleroderma, familial progressive 10.3
38 hepatocellular adenoma 10.3
39 glomerulonephritis 10.3
40 antiphospholipid syndrome 10.3
41 vasculitis 10.3
42 polyarteritis nodosa 10.3
43 splenic artery aneurysm 10.2
44 myeloproliferative neoplasm 10.2
45 systemic mastocytosis 10.2
46 mastocytosis 10.2
47 congenital hepatic fibrosis 10.2
48 pulmonary hypertension, primary, 1 10.2
49 portal hypertension, noncirrhotic 10.2
50 neutropenia 10.2

Graphical network of the top 20 diseases related to Nodular Regenerative Hyperplasia:



Diseases related to Nodular Regenerative Hyperplasia
Sources

Symptoms & Phenotypes for Nodular Regenerative Hyperplasia

About this section

Human phenotypes related to Nodular Regenerative Hyperplasia:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
2 abnormality of the hepatic vasculature 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Regenerative Hyperplasia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 EFNB2 F3 GFER ITPA JAG1 NOTCH1
2 cellular MP:0005384 9.95 EFNB2 F3 GFER ITPA JAG1 NOTCH1
3 hematopoietic system MP:0005397 9.92 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
4 cardiovascular system MP:0005385 9.91 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
5 mortality/aging MP:0010768 9.81 EFNB2 F3 GFER ITPA JAG1 NOTCH1
6 integument MP:0010771 9.73 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
7 muscle MP:0005369 9.43 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
8 respiratory system MP:0005388 9.02 EFNB2 F3 ITPA NOTCH1 NOTCH2
Sources

Drugs & Therapeutics for Nodular Regenerative Hyperplasia

About this section

Drugs for Nodular Regenerative Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2 Analgesics, Non-Narcotic Phase 4
3 Mesalamine Phase 4 89-57-6
4 Analgesics Phase 4
5 Calcium, Dietary Phase 4
6 Calcium Supplement Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9
Calcium Nutraceutical Phase 4 7440-70-2 271
10
Propranolol Approved, Investigational Phase 3 525-66-6 4946
11
Apixaban Approved Phase 3 503612-47-3 10182969
12 Adrenergic beta-Antagonists Phase 3
13 Antihypertensive Agents Phase 3
14 Adrenergic Agents Phase 3
15 Adrenergic Antagonists Phase 3
16 Anti-Arrhythmia Agents Phase 3
17 Vasodilator Agents Phase 3
18 Neurotransmitter Agents Phase 3
19 Liver Extracts Phase 3
20 Antithrombins Phase 3
21 Antithrombin III Phase 3
22 Serine Proteinase Inhibitors Phase 3
23 Factor Xa Inhibitors Phase 3
24
protease inhibitors Phase 3
25 HIV Protease Inhibitors Phase 3
26 Anticoagulants Phase 3
27
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
28
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
30
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
31
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
32
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
33
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
34 Pharmaceutical Solutions Phase 1, Phase 2
35 Antirheumatic Agents Phase 1, Phase 2
36 Immunoglobulins Phase 1, Phase 2
37 Antibodies Phase 1, Phase 2
38 Anti-Infective Agents Phase 1, Phase 2
39 Antibodies, Monoclonal Phase 1, Phase 2
40 Alkylating Agents Phase 1, Phase 2
41 Antifungal Agents Phase 1, Phase 2
42 Immunosuppressive Agents Phase 1, Phase 2
43 Anti-Bacterial Agents Phase 1, Phase 2
44 Immunologic Factors Phase 1, Phase 2
45 Antineoplastic Agents, Immunological Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 1, Phase 2
47
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
48
Norethindrone Approved 68-22-4 6230
49
Polyestradiol phosphate Approved 28014-46-2
50
Epinephrine Approved, Vet_approved 51-43-4 5816

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. Unknown status NCT01789294 Phase 4 Mesalamine
2 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
3 Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Recruiting NCT04007289 Phase 3 Apixaban;Placebo
4 Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease Completed NCT01420211 Phase 1, Phase 2 Primovist® 0,25 mmol/ml solution for injection
5 High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease Recruiting NCT02629120 Phase 1, Phase 2 Campath;Busulfan IV;Sirolimus;cyclophosphamide
6 Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. Unknown status NCT02767206
7 Prevalence of Mutations of Glucocorticoid Receptors in Bilateral Adrenal Hyperplasia Unknown status NCT02810496
8 Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice Unknown status NCT01329458
9 Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection Unknown status NCT03323359
10 Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma Unknown status NCT02238769
11 Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours - A Pilot Study Unknown status NCT02827786
12 Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy Completed NCT00825617 Hormone replacement therapy
13 Investigation of Changes in ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension Completed NCT04267406
14 Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension Completed NCT02635815
15 "The Fingerprint: Spoke-wheel Sign" of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique Completed NCT02737865 Sonazoid
16 Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWEâ„¢) for Characterisation of Liver Tumors Completed NCT02156700
17 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection Completed NCT03208192
18 Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) in Non-Cirrhotic Patients - A Double Blind International Multicenter Study Completed NCT01234701
19 Evaluation of Sickle Cell Liver Disease Completed NCT01950429
20 The Impact of Sarcopenia, Body Composition and Other Biometric Parameters on the Postoperative Outcomes of Patients Undergoing Liver Resection for Different Indications Completed NCT03630978
21 Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI) Completed NCT00828607
22 Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism Completed NCT01567111
23 Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes Recruiting NCT00001244
24 Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program Recruiting NCT03717792
25 Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions Recruiting NCT03652636
26 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
27 Advanced Magnetic Resonance Technics for the Assessment of Liver Function Before and After Transjugular Intrahepatic Portosystemic Shunt Recruiting NCT03933891
28 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Nodular Regenerative Hyperplasia

Sources

Genetic Tests for Nodular Regenerative Hyperplasia

About this section
Sources

Anatomical Context for Nodular Regenerative Hyperplasia

About this section

MalaCards organs/tissues related to Nodular Regenerative Hyperplasia:

40
Liver, Bone Marrow, Bone, Testes, Kidney, Spleen, Myeloid
Sources

Publications for Nodular Regenerative Hyperplasia

About this section

Articles related to Nodular Regenerative Hyperplasia:

(show top 50) (show all 608)
# Title Authors PMID Year
1
Drug-induced nodular regenerative hyperplasia. 52 61
24879987 2014
2
Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. 61 52
22554152 2012
3
Biliary Atresia Patients With Successful Kasai Portoenterostomy Can Present With Features of Obliterative Portal Venopathy. 61
32187144 2020
4
Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy. 61
31994248 2020
5
Spectrum of Hepatic Manifestations of Common Variable Immunodeficiency. 61
32187043 2020
6
Does Chemotherapy-Induced Liver Injury Impair Postoperative Outcomes After Laparoscopic Liver Resection for Colorectal Metastases? 61
32410180 2020
7
Nodular regenerative hyperplasia - An under-recognized vascular disorder of liver. 61
32164988 2020
8
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. 61
32338534 2020
9
Sinusoidal obstruction syndrome. 61
32253162 2020
10
Nodular Regenerative Hyperplasia: Expression Pattern of Glutamine Synthetase and a Potential Role for Hepatic Progenitor Cells. 61
31335486 2020
11
Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report. 61
32192389 2020
12
Nodular regenerative hyperplasia and portal hypertension are the characteristics of liver abnormalities in patients with selective immunoglobulin A deficiency. 61
32146091 2020
13
Hepatocellular adenoma(s) arising in nodular regenerative hyperplasia in a patient with systemic lupus erythematosus. 61
31810588 2020
14
The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. 61
32090622 2020
15
Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies. 61
31429968 2020
16
Liver stiffness measurement in patients with nodular regenerative hyperplasia undergoing magnetic resonance elastography. 61
31834457 2020
17
Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase (TERT) Mutation. 61
31943309 2020
18
Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis. 61
32117289 2020
19
Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders. 61
32184784 2020
20
Abernethy malformation and hepatocellular carcinoma: a serious consequence of a rare disease. 61
31911408 2020
21
Noncirrhotic Portal Hypertension Secondary to Nodular Regenerative Hyperplasia Postrenal Transplant. 61
32042840 2019
22
Recurrent metastatic breast cancer presenting with portal hypertension and pseudocirrhosis. 61
31767605 2019
23
Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. 61
31771307 2019
24
[Unknown liver lesions]. 61
31752038 2019
25
Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. 61
30625404 2019
26
Budd-Chiari Syndrome in a Patient With Simultaneous Diagnosis of Hepatic Sarcoidosis and Nodular Regenerative Hyperplasia. 61
31750374 2019
27
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 61
30462857 2019
28
Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. 61
31193692 2019
29
Clinicopathologic characteristics of de novo nodular regenerative hyperplasia in pediatric liver transplant. 61
31124197 2019
30
Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. 61
31094013 2019
31
Letter to the Editor: Is Nodular Regenerative Hyperplasia an Immune-Mediated Phenomenon? 61
30820967 2019
32
The Spectrum of Hepatic Involvement in Patients With Telomere Disease. 61
30791107 2019
33
Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. 61
31203688 2019
34
Novel IL2RG Mutation Causes Leaky TLOWB+NK+ SCID With Nodular Regenerative Hyperplasia and Normal IL-15 STAT5 Phosphorylation. 61
29939941 2019
35
Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. 61
31183008 2019
36
Porto-sinusoidal vascular disease: proposal and description of a novel entity. 61
30957754 2019
37
A case of incontinentia pigmenti associated with congenital absence of portal vein system and nodular regenerative hyperplasia. 61
30328117 2019
38
Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. 61
29775790 2019
39
Mycobacterium chimaera Hepatitis: A New Disease Entity. 61
30346305 2019
40
The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis. 61
30014488 2019
41
Idiopathic portal hypertension presenting with hepatic nodular regenerative hyperplasia after splenectomy: a case report. 61
31933916 2019
42
Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. 61
31125338 2019
43
Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver. 61
31191844 2019
44
A Novel CD3G Mutation in a Taiwanese Patient With Normal T Regulatory Function Presenting With the CVID Phenotype Free of Autoimmunity-Analysis of all Genotypes and Phenotypes. 61
31921117 2019
45
Common Variable Immunodeficiency and Liver Involvement. 61
28785926 2018
46
Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details. 61
30014586 2018
47
Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation. 61
30273196 2018
48
Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. 61
30014512 2018
49
Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine? 61
30600283 2018
50
Liver atoll sign: Nodular regenerative hyperplasia. 61
30309139 2018
Sources

Variations for Nodular Regenerative Hyperplasia

About this section
Sources

Expression for Nodular Regenerative Hyperplasia

About this section
Search GEO for disease gene expression data for Nodular Regenerative Hyperplasia.
Sources

Pathways for Nodular Regenerative Hyperplasia

About this section

Pathways related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Th17 cell differentiation 36
Show member pathways
 12.24 NOTCH2 NOTCH1 JAG1
2
Notch Signaling Pathway (WikiPathways) 1
Show member pathways
 12.19 NOTCH2 NOTCH1 JAG1
3
Wnt / Hedgehog / Notch 4
11.87 NOTCH2 NOTCH1 JAG1
4
NOTCH2 Activation and Transmission of Signal to the Nucleus 65
Show member pathways
 11.65 NOTCH2 NOTCH1 JAG1
5
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.3 PCNA NOTCH1 JAG1
6
Th2 Differentiation 64
11.16 NOTCH1 JAG1
7
Notch Signaling Pathway (sino) 66
11.11 NOTCH2 NOTCH1 JAG1
8
Angiogenesis (CST) 4
10.97 NOTCH2 NOTCH1 JAG1 F3 EFNB2
9
Notch Signaling 63
10.95 NOTCH2 NOTCH1
10
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics 60
10.89 TPMT ITPA
11
NOTCH1 regulation of human endothelial cell calcification 1
10.66 NOTCH1 JAG1
12
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits 1
10.6 NOTCH1 JAG1
13
Canonical and Non-canonical Notch signaling 1
10.56 NOTCH2 NOTCH1 JAG1
Sources

GO Terms for Nodular Regenerative Hyperplasia

About this section

Cellular components related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction GO:0005912 8.8 NOTCH1 JAG1 EFNB2

Biological processes related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.81 NOTCH1 JAG1 EFNB2
2 axon guidance GO:0007411 9.8 NOTCH2 NOTCH1 EFNB2
3 animal organ morphogenesis GO:0009887 9.76 NOTCH2 JAG1 EFNB2
4 Notch signaling pathway GO:0007219 9.72 NOTCH2 NOTCH1 JAG1
5 liver development GO:0001889 9.67 NOTCH2 NOTCH1 GFER
6 negative regulation of neuron differentiation GO:0045665 9.66 NOTCH1 JAG1
7 negative regulation of cell differentiation GO:0045596 9.65 NOTCH1 JAG1
8 humoral immune response GO:0006959 9.65 NOTCH2 NOTCH1
9 embryonic limb morphogenesis GO:0030326 9.65 NOTCH2 NOTCH1
10 keratinocyte differentiation GO:0030216 9.64 NOTCH1 JAG1
11 positive regulation of Notch signaling pathway GO:0045747 9.64 NOTCH1 JAG1
12 positive regulation of BMP signaling pathway GO:0030513 9.63 NOTCH2 NOTCH1
13 positive regulation of Ras protein signal transduction GO:0046579 9.62 NOTCH2 NOTCH1
14 aortic valve morphogenesis GO:0003180 9.61 NOTCH1 JAG1
15 inflammatory response to antigenic stimulus GO:0002437 9.61 NOTCH2 NOTCH1
16 neuronal stem cell population maintenance GO:0097150 9.6 NOTCH1 JAG1
17 cell fate determination GO:0001709 9.59 NOTCH2 JAG1
18 negative regulation of stem cell differentiation GO:2000737 9.58 NOTCH1 JAG1
19 left/right axis specification GO:0070986 9.57 NOTCH2 NOTCH1
20 cardiac septum morphogenesis GO:0060411 9.56 NOTCH1 JAG1
21 response to muramyl dipeptide GO:0032495 9.54 NOTCH1 JAG1
22 morphogenesis of an epithelial sheet GO:0002011 9.52 NOTCH2 JAG1
23 glomerular visceral epithelial cell development GO:0072015 9.51 NOTCH2 JAG1
24 interleukin-4 secretion GO:0072602 9.48 NOTCH2 NOTCH1
25 venous blood vessel morphogenesis GO:0048845 9.46 NOTCH1 EFNB2
26 ciliary body morphogenesis GO:0061073 9.43 NOTCH2 JAG1
27 regulation of developmental process GO:0050793 9.4 NOTCH2 NOTCH1
28 distal tubule development GO:0072017 9.37 NOTCH1 JAG1
29 negative regulation of growth rate GO:0045967 9.32 NOTCH2 NOTCH1
30 positive regulation of aorta morphogenesis GO:1903849 9.26 NOTCH1 EFNB2
31 positive regulation of cardiac epithelial to mesenchymal transition GO:0062043 9.16 NOTCH1 JAG1
32 pulmonary valve morphogenesis GO:0003184 9.13 NOTCH2 NOTCH1 JAG1
33 Notch signaling involved in heart development GO:0061314 8.8 NOTCH2 NOTCH1 JAG1

Molecular functions related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Notch binding GO:0005112 8.62 NOTCH1 JAG1
Sources

Sources for Nodular Regenerative Hyperplasia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....